Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Kestra Medical Technologies (KMTS) stock in plain English

Free brief · no signupStart here
KMTSPublished Nov 19, 2026
Kestra Medical Technologies Ltd
Healthcare · Medical Instruments & Supplies
Sells wearable defibrillator systems that detect irregular heartbeats and deliver shocks to protect high-risk cardiac patients.
Assets:
ASSURE WCDWearable cardiac defibrillator product line
CareStationCloud software for continuous patient tracking
Kirkland baseCorporate and development offices in Washington
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

62
OPS ScoreOperating finances
Latest quote
-5.87%$26.63
$1.59B
n/a (loss)
$106.74M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was KMTS. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Kestra Medical Technologies (KMTS) do?

Kestra Medical Technologies Ltd (KMTS) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Sells wearable defibrillator systems that detect irregular heartbeats and deliver shocks to protect high-risk cardiac patients. Designs wearable cardioverter defibrillators tailored to fit varied patient anatomies, with a specific focus on women. It is worth $1.59B on the market and sold $106.74M over the last year.

Market cap
$1.59B
P/E ratio
None (reported a loss)
Annual sales
$106.74M
Sector
Healthcare
Industry
Medical Instruments & Supplies
Brief updated
Nov 19, 2026

Brands and businesses behind KMTS

  • ASSURE: Sells wearable automated defibrillators that earn revenue through device sales and monthly patient prescription rentals.
  • Kestra CareStation: Supplies cloud software that displays continuous cardiac diagnostic data collected from wearable defibrillator users.

KMTS’s flags, in plain English

Each flag is a number from Kestra Medical Technologies’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Stupid Cash

Can pay this year's bills 4.7 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Insiders Hold

Insiders own 59.2% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Low debt

Low debt, only 34% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Burning Cash

Losing money, profit margin of -140.4%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more green flag and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about KMTS

How big is Kestra Medical Technologies?

Kestra Medical Technologies’ market cap is $1.59B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $106.74M: what customers paid the company over the last year, before any costs.

What is KMTS’s P/E ratio?

KMTS has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with KMTS?

The business depends almost completely on the commercial adoption of its single ASSURE device line. That is one risk on Kestra Medical Technologies’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Kestra Medical Technologies’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. KMTS’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card